| Dr Daniel G Christo, DO | |
|
210 Ohio River Blvd, Baden, PA 15005-1914 | |
| (724) 869-6002 | |
| Not Available |
| Full Name | Dr Daniel G Christo |
|---|---|
| Gender | Male |
| Speciality | Family Medicine |
| Location | 210 Ohio River Blvd, Baden, Pennsylvania |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1386660595 | NPI | - | NPPES |
| 0016054990010 | Medicaid | PA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 0S009335L (Pennsylvania) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Daniel G Christo, DO 210 Ohio River Blvd, Baden, PA 15005-1914 Ph: (724) 869-6002 | Dr Daniel G Christo, DO 210 Ohio River Blvd, Baden, PA 15005-1914 Ph: (724) 869-6002 |
News Archive
Some high school football players exhibit measurable brain changes after a single season of play even in the absence of concussion, according to a study presented today at the annual meeting of the Radiological Society of North America (RSNA).
Plants could act as safe, speedy factories for growing antibodies for personalized treatments against a common form of cancer, according to new findings from the Stanford University School of Medicine. The findings came in the first human tests of an injectable vaccine grown in genetically engineered plants.
Arjen Dondorp, deputy director of the Mahidol Oxford Tropical Research Unit at Mahidol University in Bangkok, Thailand, and colleagues discuss the need to combat antimalarial drug resistance in this New England Journal of Medicine opinion piece, writing, "Researchers, funders, and policy leaders must recognize the urgency of the problem, take action to address simultaneously several important knowledge gaps, and focus immediately on eliminating the threat of artemisinin resistance."
Array BioPharma Inc. today announced results from a randomized Phase 2 placebo-controlled study conducted by AstraZeneca comparing the efficacy of selumetinib in combination with docetaxel with docetaxel alone in the second-line treatment of 87 patients prospectively selected with KRAS-mutant, locally advanced or metastatic non-small cell lung cancer.
TLC Vision Corporation, North America's premier eye care services company, today announced that further to its press release issued on December 21, 2009, the United States Bankruptcy Court for the District of Delaware has granted the relief the Company and two of its wholly-owned subsidiaries, TLC Vision (USA) Corporation and TLC Management Services Inc., requested in its "First Day Motions" filed in conjunction with its voluntary petitions under Chapter 11 of the U.S. Bankruptcy Code.
› Verified 9 days ago
Dr. Jeffery P Hein, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 210 Ohio River Blvd, Baden, PA 15005 Phone: 724-869-6002 Fax: 724-869-6005 |